The Dow Jones Industrial Average (+0.4%) and S&P 500 (+0.2%) rallied to new record highs on Tuesday with the Dow crossing above the 18,000 mark for the first time. However, widespread losses in the biotechnology group prevented the Nasdaq Composite (-0.3%) from taking part in the rally.
Equity indices began the day in the green after a better than expected revision to Q3 GDP (5.0%; Briefing.com consensus 4.3%) provided a pre-market boost. The GDP report was a bright spot among a torrent of mostly disappointing data, which was taken in stride by the market.
Nine of ten sectors registered gains with the energy space (+1.3%) ending in the lead. The growth-sensitive sector opened ahead of other groups and held the lead into the close. Crude oil, meanwhile, settled higher by 3.1% at $57.09/bbl and continued its advance in electronic trading with the move taking place even as the Dollar Index (90.13, +0.36) climbed 0.4%.
The energy sector was followed closely by materials (+0.8%) while the remaining cyclical groups also settled ahead of the broader market. Consumer discretionary (+0.6%) and financials (+0.6%) enjoyed broad support while the technology sector (+0.3%) rallied behind its top components like Google (GOOGL 538.77, +6.47), Intel (INTC 37.43, +0.22), and Microsoft (MSFT 48.45, +0.47). The three names gained between 0.6% and 1.2%, but the largest component—Apple (AAPL 112.54, -0.40)—shed 0.4% and kept the Nasdaq pressured.
However, Nasdaq's woes were not isolated to its largest member. Biotech names retreated across the board with the iShares Nasdaq Biotechnology ETF (IBB 294.70, -14.38) dipping below its 50-day average (294.47). The biotech ETF was able to reclaim that level ahead of the close, but still ended the day lower by 4.7%. For its part, the health care sector (-2.2%) was the only group that ended behind the S&P 500.
The underperformance of biotechnology prevented the S&P 500 from extending its gain, while the price-weighted Dow Jones Industrial Average benefitted from containing just four health care names with two of the four priced below $60/share. In total, only five Dow components registered losses while the two largest listings—Visa (V 265.26, +1.05) and Goldman Sachs (GS 195.50, +1.06) gained 0.4% and 0.6%, respectively. Today's outperformance extended the Dow's year-to-date gain to 8.7%, but the index remains behind the S&P 500, which has added 12.7% so far in 2014.
Elsewhere among Dow members, shares of Coca-Cola (KO 42.97, +0.62) gained 1.5% after The Wall Street Journal reported the company plans to cut between 1,000 and 2,000 jobs globally. As for the broader consumer staples sector (+0.8%), the countercyclical group ended among the leaders.
Treasuries ended near their lows with the 10-yr yield spiking ten basis points to 2.26%.
Today's participation was below average with fewer than 700 million shares changing hands at the NYSE floor.
Economic data was plentiful, including GDP, Durable Orders, FHFA Housing Price Index, Michigan Sentiment, Personal Income/Spending, and New Home Sales:
- Third quarter GDP was revised up to 5.0% in the third estimate after an originally reported 3.9% gain, which was the largest increase since a 6.9% spike in Q3 2003
- The consensus expected GDP to be revised up to 4.3%
- Real final sales were revised up to 5.0% from 4.1%, which was the largest increase since Q1 2006 when sales climbed 5.5%
- Consumption was revised up to 3.2% from 2.2% after increasing 2.5% in Q2 2014
- Durable goods orders declined 0.7% in November after increasing a downwardly revised 0.3% (from 0.4%) in October
- The consensus expected an increase of 2.7%
- A large portion of the miss was a result of seasonal adjustments impacting nondefense aircraft orders
- Excluding transportation, durable goods orders declined 0.4% while the consensus expected an increase of 1.0%
- The October Housing Price Index from the FHFA rose 0.6%, which followed an unchanged reading in September
- New home sales in November hit an annualized rate of 438,000, which was down from the revised October rate of 445,000 (from 458,000) and worse than the rate of 460,000 that had been broadly expected by the consensus
- The University of Michigan Consumer Sentiment Index was virtually unchanged at 93.6 (from 93.8) in the final December reading while the consensus expected no change
- The December sentiment reading marked the highest point since January 2007
- Personal income increased 0.4% in November while the consensus expected an increase of 0.5%
- Personal spending increased 0.6% in November while the consensus expected an increase of 0.5%
- Core PCE prices were flat in November while the consensus expected an uptick of 0.1%
There is no economic data on tomorrow's schedule with the session scheduled to end early at 13:00 ET.
- Nasdaq Composite +14.1% YTD
- S&P 500 +12.7% YTD
- Dow Jones Industrial Average +8.7% YTD
- Russell 2000 +3.4% YTD
+------------------------------------------------------------------------------+
BFW 12/23 17:46 Stryker Said to Plan Smith & Nephew Takeover Bid Within Weeks
+------------------------------------------------------------------------------+
Stryker Said to Plan Smith & Nephew Takeover Bid Within Weeks 2014-12-23 17:43:08.645 GMT
By Manuel Baigorri, David Welch and Dinesh Nair (Bloomberg) -- Stryker Corp. is planning a takeover offer for U.K. medical device maker Smith & Nephew Plc that could happen in the coming weeks, according to people with knowledge of the matter. The U.S. producer of surgical implants plans to offer a significant premium to Smith & Nephew’s current share price, with one of the people saying it could be about 30 percent. Shares in London-based Smith & Nephew have climbed 26 percent this year, valuing the company at about 9.7 billion pounds ($15 billion). The Kalamazoo, Michigan-based company is not planning a so- called tax inversion because of the limited tax benefits and political risk, said one of the people, who asked not to be identified because deliberations are private. The U.S. government is clamping down on inversions to stop companies from moving their addresses abroad through deals to cut taxes. The bid is still being finalized and the timing could change, said the people. There’s also a chance that Stryker decides against an offer, one of them said. Representatives for Stryker and Smith & Nephew declined to comment. Medical-device companies are looking to consolidate as hospitals and insurers demand better prices from suppliers to tame rising costs. Two large manufacturers of surgical products and medical supplies, Medtronic Inc. and Covidien Plc, are in the process of completing a merger that was announced in June. Last month, Stryker was discussing the financing of a deal and potential antitrust hurdles with advisers, people familiar with the matter said at the time.
For Related News and Information: Stryker Said to Weigh Smith & Nephew Bid as Standstill Ends NSN NFJQVN6JTSEU<GO> Medtronic Agrees to Buy Device Maker Covidien for $42.9 Billion NSN N78QPT6S972F<GO> Top Stories: TOP<GO> Top Deal Stories: DTOP<GO>
--With assistance from Sonja Elmquist in New York and Makiko Kitamura in London.
To contact the reporters on this story: Manuel Baigorri in London at +44-20-3525-4457 or mbaigorri@bloomberg.net; David Welch in New York at +1-248-455-2343 or dwelch12@bloomberg.net; Dinesh Nair in London at +44-20-3525-3212 or dnair5@bloomberg.net To contact the editors responsible for this story: Aaron Kirchfeld at +44-20-3525-8830 or akirchfeld@bloomberg.net Elizabeth Fournier
M&A related: PRLS +24.9% (to be acquired by Mobius Acquisition for $7.00 per share).
Other news: CYTK +27.6% (announced expansion of collaboration for development of CK-2127107; CYTK will receive $55 mln from Astellas (ALSMY)), VNDA +17.5% (to regain US and Canadian rights to Fanapt; Novartis (NVS) to purchase $25 million of Vanda common stock), ICLD +11.3% (announces $6.2 mln professional services contract for a Tier 1 Carrier), OSIR +5.6% (announces exclusive, worldwide partnership with Stryker Corp (SYK) for the commercialization and development of Osiris' viable bone matrix tissue form), CHK +5.5% (announced the closing of its asset sale to Southwestern Energy, authorized a $1 bln common stock repurchase program), ARIA +2.7% (Co and Otsuka Pharma announced agreement on Iclusig in Japan and nine other Asian countries), TASR +2.3% (announced purchase from Pasco County, FL), SDRL +1.9% (still checking), GILD +1.8% (partially rebounding from yesterday's selloff), BCRX +1.6% (announced results from a proof-of-concept study of its antiviral BCX4430 for the treatment of experimental Ebola virus), NBG +-3.6% (Greek elections fell short of electing PM).
Analyst comments: SBUX +0.6% (named a Top Pick for 2015 at Piper Jaffray), GPRO +0.3% (positive analyst comments; co has smaller lockup expiration today), JAH +0.3% (target raised to $56 from $51, maintain Overweight at Piper Jaffray).